PharmacoEconomics

, Volume 29, Issue 10, pp 839–861

A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease

Implications for Policy

Authors

    • Boston Health Economics, Inc
  • Lisa M. Lines
    • Boston Health Economics, Inc
  • Daniel E. Weiner
    • Tufts Medical Center
  • Peter J. Neumann
    • Tufts Medical Center
  • Christine Nichols
    • Boston Health Economics, Inc
  • Lauren Rodriguez
    • Boston Health Economics, Inc
  • Irene Agodoa
    • Amgen, Thousand
  • Tracy Mayne
    • Davita Clinical Research
Review Article

DOI: 10.2165/11588390-000000000-00000

Cite this article as:
Menzin, J., Lines, L.M., Weiner, D.E. et al. Pharmacoeconomics (2011) 29: 839. doi:10.2165/11588390-000000000-00000

Abstract

Given rising healthcare costs and a growing population of patients with chronic kidney disease (CKD), there is an urgent need to identify health interventions that provide good value for money.

For this review, the English-language literature was searched for studies of interventions in CKD reporting an original incremental cost-utility (cost per QALY) or cost-effectiveness (cost per life-year) ratio. Published cost studies that did not report cost-effectiveness or cost-utility ratios were also reviewed. League tables were then created for both cost-utility and cost-effectiveness ratios to assess interventions in patients with stage 1–4 CKD, waitlist and transplant patients and those with end-stage renal disease (ESRD). In addition, the percentage of cost-saving or dominant interventions (those that save money and improve health) was compared across these three disease categories.

A total of 84 studies were included, contributing 72 cost-utility ratios, 20 cost-effectiveness ratios and 42 other cost measures. Many of the interventions were dominant over the comparator, indicating better health outcomes and lower costs. For the three disease categories, the greatest number of dominant or cost-saving interventions was reported for stage 14 CKD patients, followed by waitlist and transplant recipients and those with ESRD (91%, 87% and 55% of studies reporting a dominant or cost-saving intervention, respectively).

There is evidence of opportunities to lower costs in the treatment of patients with CKD, while either improving or maintaining the quality of care. In order to realize these cost savings, efforts will be required to promote and effectively implement changes in treatment practices.

Copyright information

© Adis Data Information BV 2011